DOV Pharmaceutical Inc.
150 Pierce Street
Somerset,
NJ 08873
United States - Map
Phone: 732-907-3600
Fax: 732-907-3799
Web Site: http://www.dovpharm.com
| DOV Pharmaceutical, Inc., a biopharmaceutical company, engages in the discovery, in-licensing, and development of novel drug candidates for central nervous system disorders. Its product candidate include DOV 21,947, a triple reuptake inhibitor, which is in Phase II clinical trials for depression, as well as in preclinical studies for obesity; Bicifadine for the treatment of pain or analgesics, which is in Phase II/Phase III(2) clinical trials; DOV diltiazem for the treatment of hypertension and angina is in Phase I/III(3); and DOV 102,677, which is in Phase I(4) for alcohol abuse. The company also involves in the preclinical discovery and development programs, such as DOV 216,419 which is in Pre-IND(5) preclinical trails for depression and pain; and Uptake inhibitors and GABA modulators for various central nervous system disorders. In addition, DOV Pharmaceutical develops Indiplon, a program subject to regulatory review for the treatment of insomnia. It has strategic collaborations and licensing agreements with XTL Biopharmaceuticals, Inc., for bicifadine; Blue Note Pharmaceuticals, Inc., for DOV diltiazem; and Neurocrine Biosciences, Inc., for indiplon, as well as Wyeth Holdings Corporation. The company was founded in 1995 and is headquartered in Somerset, New Jersey. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Arnold S. Lippa Ph.D., 61
Co-Founder, Exec. Chairman and Member of Scientific Advisory Board |
N/A
| N/A | Ms. Barbara G. Duncan , 43
Chief Exec. Officer, Chief Financial Officer, Treasurer |
$
429.00K |
$
913.00K | Dr. Phil Skolnick Ph.D., D.Sc. (hon), 61
Pres and Chief Scientific Officer |
$
405.00K |
$
885.00K | Dr. Robert Cancro M.D.,
Co-Founder and Chairman of Scientific Advisory Board |
N/A
| N/A | Mr. William Kaltnecker , 63
Principal Accounting officer and Controller |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-07
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.83% Nasdaq 0.00%
Profile
